| Identification | Back Directory | [Name]
EC-5026 | [CAS]
1809885-32-2 | [Synonyms]
EC-5026
EC-5062
BPN-19186
Urea, N-[3-fluoro-4-(trifluoromethoxy)phenyl]-N'-[1-[(2S)-2-methyl-1-oxobutyl]-4-piperidinyl]- | [Molecular Formula]
C18H23F4N3O3 | [MOL File]
1809885-32-2.mol | [Molecular Weight]
405.39 |
| Chemical Properties | Back Directory | [Boiling point ]
466.8±45.0 °C(Predicted) | [density ]
1.30±0.1 g/cm3(Predicted) | [solubility ]
DMSO:250.0(Max Conc. mg/mL);616.69(Max Conc. mM) | [form ]
A solid | [pka]
12.94±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
EC5026 (BPN-19186) is a first-in-class, non-opioid and orally active soluble Epoxide Hydrolase (sEH) inhibitor. EC5026 shows efficacy for inflammatory and neuropathic pain[1]. | [in vivo]
EC5026 (BPN-19186) has already shown efficacy for treating pain with no apparent adverse or addictive effects in laboratory animals and relieving naturally occurring pain in dogs, cats and horses[1]. | [References]
[1] EicOsis Announces FDA Acceptance of IND Application for EC5026, the First Soluble Epoxide Hydrolase Inhibitor to Treat Pain.2019. |
|
|